Zobrazeno 1 - 10
of 257
pro vyhledávání: '"Nancy U. Lin"'
Autor:
Yu Gu, Tarek Taifour, Tung Bui, Dongmei Zuo, Alain Pacis, Alexandre Poirier, Sherif Attalla, Anne-Marie Fortier, Virginie Sanguin-Gendreau, Tien-Chi Pan, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Morag Park, Michel L. Tremblay, Lewis A. Chodosh, Rinath Jeselsohn, William J. Muller
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Recurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumo
Externí odkaz:
https://doaj.org/article/ce14835d262d4ceaae4ee74374578c4b
Autor:
Albert Grinshpun, Douglas Russo, Wen Ma, Ana Verma, Francisco Hermida-Prado, Shira Sherman, Giorgio Gaglia, Sheheryar Kabraji, Gregory Kirkner, Melissa E. Hughes, Nancy U. Lin, Zachary Sandusky, Agostina Nardone, Cristina Guarducci, Quang-De Nguyen, Sandro Santagata, Zsuzsanna Nagy, Rinath Jeselsohn
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone receptor-positive breast cancer. These mutations confer endocrine resistance that remains est
Externí odkaz:
https://doaj.org/article/7c7a103652a4404eac1f649798184d56
Autor:
Stacey Pan, Jayant Y. Gadrey, Sarah Sammons, Nancy U. Lin, Sara M. Tolaney, Paolo Tarantino, Ilana Schlam
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. De
Externí odkaz:
https://doaj.org/article/228052a30a8c47edb31a02d73a0d9afb
Autor:
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari A. King, Anna Weiss, Ann H. Partridge, Brittany L. Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast ca
Externí odkaz:
https://doaj.org/article/a6787b2746714e679389db17fc729577
Autor:
Paolo Tarantino, Julieta Leone, Carlos T. Vallejo, Rachel A. Freedman, Adrienne G. Waks, Olga Martínez-Sáez, Ana Garrido-Castro, Filipa Lynce, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney, Jose P. Leone
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-4 (2024)
Abstract To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T
Externí odkaz:
https://doaj.org/article/1fa3677d68434dd1aa72422112ac6937
Autor:
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, Alyssa Pereslete, Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-labe
Externí odkaz:
https://doaj.org/article/fbf0b09b34034b3ca24835f1877b47b7
Autor:
Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tolaney, Nancy U. Lin, Deborah A. Dillon, Stuart J. Schnitt, Peter K. Sorger, Elizabeth A. Mittendorf, Sandro Santagata
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-22 (2024)
Abstract Emerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with therapy resistance, highlighting the need for new strategies to assess HER2 ITH. A promising approach is leveraging multiplexed tissue analysis techniques s
Externí odkaz:
https://doaj.org/article/3efb1bd4ddfe4838842869755c17c107
Autor:
Paolo Tarantino, Hersh Gupta, Melissa E. Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany L. Bychkovsky, Simona DiLascio, Lynette Sholl, Laura MacConaill, Neal Lindeman, Bruce E. Johnson, Matthew Meyerson, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry Long, Eric P. Winer, Deborah Dillon, Giuseppe Curigliano, Andrew D. Cherniack, Sara M. Tolaney, Nancy U. Lin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast cancer undergoing next-generation sequencing from 7/2013-12/2020,
Externí odkaz:
https://doaj.org/article/5c5258c1093e4d42ab2f76c5fe3ba511
Autor:
Nancy U. Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark Pegram
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radio
Externí odkaz:
https://doaj.org/article/083932eab9b845db9719ffc2d667e0c8
Autor:
Ana C. Garrido-Castro, Meredith M. Regan, Samuel M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. Rosenbluth, Caroline Block, Laura E. Warren, Jennifer R. Bellon, Eren Yeh, Beth T. Harrison, Elizabeth Troll, Nancy U. Lin, Sara M. Tolaney, Beth Overmoyer, Filipa Lynce
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20–30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into l
Externí odkaz:
https://doaj.org/article/f90179b9e9ad4de3a518ebb7c8c12a8f